Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subcutaneous para-umbilical low-grade sarcoma with rare FUS::NFATC4 fusion.

Pathology·2026
Same author

Maintenance Liposomal Doxorubicin Following Induction Doxorubicin in Soft Tissue Sarcoma: A Single-Center Observational Study.

Current oncology (Toronto, Ont.)·2026
Same author

Novel perineurioma-like soft tissue tumour with SETD1A::FOSB fusion.

Pathology·2026
Same author

Novel FGL2::PDGFD and TGFBI::PDGFB Fusions Expand the Molecular Spectrum of Dermatofibrosarcoma Protuberans.

Genes, chromosomes & cancer·2026
Same author

EP300::VGLL3 fused rhabdomyoblastic tumor revisited: Is the label "rhabdomyosarcoma" justified?

Virchows Archiv : an international journal of pathology·2026
Same author

A Real-World Analysis of Outcomes in CIC-Rearranged Sarcomas: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study.

Cancer medicine·2026

Related Experiment Video

Updated: Mar 27, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K

Dermatofibrosarcoma protuberans: from translocation to targeted therapy.

Jonathan Noujaim1, Khin Thway1, Cyril Fisher1

  • 1Sarcoma Unit, Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK.

Cancer Biology & Medicine
|January 19, 2016
PubMed
Summary

Dermatofibrosarcoma protuberans (DFSP) is a rare skin cancer. Targeted therapy with imatinib has improved treatment for advanced DFSP, offering new hope for patients.

Keywords:
Dermatofibrosarcoma protuberans (DFSP)Mohs micrographic surgery (MMS)imatinibtargeted therapytranslocation

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.9K

Related Experiment Videos

Last Updated: Mar 27, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.8K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
09:33

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens

Published on: August 25, 2023

1.9K

Area of Science:

  • Oncology
  • Dermatology
  • Genetics

Background:

  • Dermatofibrosarcoma protuberans (DFSP) is the most common dermal sarcoma, a low-grade malignant neoplasm with high local recurrence rates.
  • DFSP typically affects middle-aged adults and is characterized by slow growth and low metastatic potential.
  • Traditional treatments like surgery and radiation are effective for localized disease, but systemic options were limited.

Purpose of the Study:

  • To review the epidemiological, clinical, histological, and genetic characteristics of DFSP.
  • To update readers on current management strategies for DFSP.
  • To highlight the impact of targeted therapy on DFSP treatment.

Main Methods:

  • Review of existing literature on DFSP.
  • Analysis of epidemiological data.
  • Summary of clinical, histological, and genetic findings.
  • Evaluation of treatment outcomes.

Main Results:

  • DFSP exhibits a unique translocation, t(17;22)(COL1A1;PDGFB), in a majority of cases.
  • Imatinib, a tyrosine kinase inhibitor, has shown significant efficacy in treating systemic DFSP.
  • Imatinib targets PDGFβR, ABL, and KIT, revolutionizing systemic therapy for DFSP.

Conclusions:

  • DFSP management has been transformed by the understanding of its genetic basis.
  • Imatinib represents a breakthrough in systemic therapy for DFSP, improving patient outcomes.
  • Continued research into DFSP pathogenesis and treatment is crucial.